U.S. Patient and Trademark Office, U.S. DE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10572523			
Filing Date		2006-03-21			
First Named Inventor	Shab	tai BAUER			
Art Unit		1652			
Examiner Name	Unkn	own			
Attornov Docket Numb	~-	2499 036			

					U.S.I	PATENTS			Remove	1	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [)ate	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Publication Code ¹ Date			Name of Patentee of Applicant Rele			es,Columns,Lines where evant Passages or Relevant ires Appear		
	1										
If you wis	h to a	dd additional U.S. Publ				n information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	or '	vhere Re	or Relevant	
	1	2002/0048176	wo		A1	2002-06-20	Bayer Corporation				
	2	2000/0017227	wo		A1	2000-03-30	American National Cross	Red			Г
	3	1997/0009350	wo		A1	1997-03-13	PPL Therapeutics				С

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10572523		
iling Date		2006-03-21		
irst Named Inventor Shabt		ai BAUER		
Art Unit		1652		
Examiner Name	Unkno	own		
Mamou Docket Numb	or	2400 026		

If you wisl	h to a	dd add	ditional F	oreign P	atent D	Ocum	ent cit	ation in	nforma	ion pleas	e click the Add bu	tton	Adı	i		
					NO	N-PA	TENT	LITER	ATUR	E DOCU	MENTS		Remo	ove		
Examinor Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs									
	1															
If you wis	h to a	dd add	ditional r	on-pater	t literat	ture do	ocume	nt citat	ion inf	rmation	please click the A	dd bu	utton	Add		
							EXA	MINER	SIGN	TURE						
Examiner	Signa	ture									Date Considered	1				
											ance with MPEP of next communicat				rough a	

1 See Kins Code of USFTO Planto Documents at year, <u>USFTO COD</u> or MEPD 910.4. ² Enter office that issued the cocurrent, by the two-letter code (WPD Standard 513.). ² The Japanese parted coverents, the relication to the year of the region of the Emperor must proceed the serial number of the papert document. ² Nicid of Cocurrent by the appropriate symbols as indicated on the document under WPD Standard 51.16 if goostile. ³ Applicant is to place a check mark here if English intraguage streamlistion a statistical or statistical or statistical statistics.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10572523		
Filing Date		2006-03-21		
First Named Inventor Shab		tai BAUER		
Art Unit		1652		
Examiner Name Unknown		own		
Attorney Docket Number		2488.036		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. Sex 37 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Jeff Rothenberg, Esq./	Date (YYYY-MM-DD)	2006-11-07
Name/Print	Jeff Rothenhern	Registration Number	26429

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.